- Home
- CTOR vs VERU Comparison
CTOR vs VERU Comparison
Compare CTOR & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- VERU
- Stock Information
- Founded
- CTOR 2021
- VERU 1971
- Country
- CTOR United States
- VERU United States
- Employees
- CTOR N/A
- VERU N/A
- Industry
- CTOR
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- VERU Health Care
- Exchange
- CTOR NYSE
- VERU Nasdaq
- Market Cap
- CTOR 89.9M
- VERU 107.2M
- IPO Year
- CTOR N/A
- VERU 1990
- Fundamental
- Price
- CTOR $1.30
- VERU $0.74
- Analyst Decision
- CTOR Strong Buy
- VERU Strong Buy
- Analyst Count
- CTOR 2
- VERU 4
- Target Price
- CTOR $4.50
- VERU $4.00
- AVG Volume (30 Days)
- CTOR 275.1K
- VERU 1.6M
- Earning Date
- CTOR 12-27-2024
- VERU 02-06-2025
- Dividend Yield
- CTOR N/A
- VERU N/A
- EPS Growth
- CTOR N/A
- VERU N/A
- EPS
- CTOR N/A
- VERU N/A
- Revenue
- CTOR N/A
- VERU $16,886,419.00
- Revenue This Year
- CTOR N/A
- VERU N/A
- Revenue Next Year
- CTOR N/A
- VERU N/A
- P/E Ratio
- CTOR N/A
- VERU N/A
- Revenue Growth
- CTOR N/A
- VERU 3.62
- 52 Week Low
- CTOR $0.85
- VERU $0.36
- 52 Week High
- CTOR $49.00
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- VERU 56.66
- Support Level
- CTOR N/A
- VERU $0.63
- Resistance Level
- CTOR N/A
- VERU $0.88
- Average True Range (ATR)
- CTOR 0.00
- VERU 0.09
- MACD
- CTOR 0.00
- VERU 0.00
- Stochastic Oscillator
- CTOR 0.00
- VERU 49.11
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.